196 related articles for article (PubMed ID: 28275035)
1. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA; Aminawung JA; Abu-Khalaf MM; Evans SB; Su K; Mehta R; Wang SY; Gross CP
J Natl Compr Canc Netw; 2017 Mar; 15(3):346-354. PubMed ID: 28275035
[No Abstract] [Full Text] [Related]
2. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
3. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
4. Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment.
Kozick Z; Hashmi A; Dove J; Hunsinger M; Arora T; Wild J; Shabahang M; Blansfield J
Am J Surg; 2018 Apr; 215(4):686-692. PubMed ID: 28606707
[TBL] [Abstract][Full Text] [Related]
5. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
[TBL] [Abstract][Full Text] [Related]
6. Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Troester MA; Carey LA; Wheeler SB
Breast Cancer Res Treat; 2015 Aug; 153(1):191-200. PubMed ID: 26216535
[TBL] [Abstract][Full Text] [Related]
7. Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.
Acuna N; Plascak JJ; Tsui J; Stroup AM; Llanos AAM
Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34065945
[TBL] [Abstract][Full Text] [Related]
8. The effect of Oncotype DX
Rabie MA; Rankin A; Burger A; Youssef M
Ann R Coll Surg Engl; 2019 Nov; 101(8):596-601. PubMed ID: 31219316
[TBL] [Abstract][Full Text] [Related]
9. Underutilization of gene expression profiling for early-stage breast cancer in California.
Cress RD; Chen YS; Morris CR; Chew H; Kizer KW
Cancer Causes Control; 2016 Jun; 27(6):721-7. PubMed ID: 27097910
[TBL] [Abstract][Full Text] [Related]
10. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
11. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
12. Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.
Moore J; Wang F; Pal T; Reid S; Cai H; Bailey CE; Zheng W; Lipworth L; Shu XO
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):821-830. PubMed ID: 35064066
[TBL] [Abstract][Full Text] [Related]
13. Influence of provider factors and race on uptake of breast cancer gene expression profiling.
Reeder-Hayes KE; Wheeler SB; Baggett CD; Zhou X; Meng K; Roberts MC; Carey LA; Meyer AM
Cancer; 2018 Apr; 124(8):1743-1751. PubMed ID: 29338090
[TBL] [Abstract][Full Text] [Related]
14. Adherence Disparities and Utilization Trends of Oncotype Dx Assay: A National Cancer Database Study.
Chen S; Thacker C; Wang S; Young KA; Hoffman RL; Blansfield JA
J Surg Res; 2023 Jun; 286():65-73. PubMed ID: 36758322
[TBL] [Abstract][Full Text] [Related]
15. Socioeconomic and racial disparities in the selection of chest wall boost radiation therapy in californian women after mastectomy.
Hess C; Lee A; Fish K; Daly M; Cress RD; Mayadev J
Clin Breast Cancer; 2015 Jun; 15(3):212-8. PubMed ID: 25499694
[TBL] [Abstract][Full Text] [Related]
16. The Role of Socioeconomic Status and Health Care Access in Breast Cancer Screening Compliance Among Hispanics.
Jadav S; Rajan SS; Abughosh S; Sansgiry SS
J Public Health Manag Pract; 2015; 21(5):467-76. PubMed ID: 25756197
[TBL] [Abstract][Full Text] [Related]
17. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
[No Abstract] [Full Text] [Related]
18. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
[TBL] [Abstract][Full Text] [Related]
19. Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004-2009.
Yeboa DN; Xu X; Jones BA; Soulos P; Gross C; Yu JB
Am J Clin Oncol; 2016 Dec; 39(6):568-574. PubMed ID: 24879475
[TBL] [Abstract][Full Text] [Related]
20. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
Hoskins KF; Danciu OC; Ko NY; Calip GS
JAMA Oncol; 2021 Mar; 7(3):370-378. PubMed ID: 33475714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]